In the last years, preclinical and clinical research focused on targeting different pathways involved in tumor growth, such as PI3K/Akt/mTOR, cyclinD/CDK/pRb pathways and tumor microenvironment [103,105,106]. This evidence concerns the gene PIK3CA and neoplasm.